Media and Communications


Business Development

Thursday, January 31, 2013
Teva Announces Termination of Agreements with CureTech

JERUSALEM--(BUSINESS WIRE)--Jan. 31, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the termination of its collaboration with CureTech Ltd. "We are in the process of conducting a disciplined review of our pipeline. As we looked closely at CT-011 and the most recent clinical and biochemical data, we have made the strategic decision to invest our resources elsewhere where we can have the most impact for patients,” stated Dr. Michael Hayden, President and CEO of R&D and Chief R&D Officer. Read More »

Sunday, December 16, 2012
Teva Enters Agreement with Handok to Establish Business Venture with Significant Presence in Korean Pharmaceutical Market

- First commercial deal for Teva in East Asian territory outside Japan -- Pharmaceutical market in South Korea worth USD 14 billion – JERUSALEM & SEOUL, Korea--(BUSINESS WIRE)--Dec. 16, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Handok Pharmaceuticals Co., Ltd. (KRX: 002390) announced today their agreement to establish a business venture in South Korea, allowing Teva to gain entrance into the Korean pharmaceutical market, currently valued at approximately USD 14 billion. Under the terms of the agreement, Read More »

Tuesday, December 11, 2012
Teva and Xenon Announce Teva’s World Wide License of Xenon’s Pain Drug XEN402

XEN402 is a Strategic Fit for Teva’s Commercial, R&D and Technology focus in CNS and Pain JERUSALEM & BURNABY, British Columbia--(BUSINESS WIRE)--Dec. 11, 2012-- Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and Xenon Pharmaceuticals Inc. (Xenon) announced today that they have entered into a collaborative development and exclusive worldwide license for XEN402. XEN402 is currently in clinical development for a variety of painful disorders. This product specifically targets sodium channels which are abundantly found in Read More »

Thursday, September 27, 2012
Teva Expands Central Nervous System (CNS) Development Pipeline with Acquisition of Huntexil® Development Program Rights from NeuroSearch A/S

Drug candidate to be assessed for managing voluntary motor disturbances in Huntington disease JERUSALEM--(BUSINESS WIRE)--Sep. 27, 2012-- Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced today that it has concluded an Asset Transfer Agreement with NeuroSearch A/S of Denmark (OMX: NEUR) to purchase all rights, assets and obligations relating to Huntexil® (pridopidine / ACR16), a drug candidate being developed for the symptomatic treatment of hand movement, balance and gait disturbances in Huntington disease (HD). Under Read More »

Thursday, November 03, 2011
The Procter & Gamble Company and Teva Pharmaceutical Industries Announce Formation of New Consumer Health Care Partnership

New Joint Venture, to be named "PGT Healthcare," has the potential to reach double-digit sales growth and $4 billion in sales towards end- of- decade CINCINNATI & JERUSALEM, Nov 03, 2011 (BUSINESS WIRE) -- The Procter & Gamble Company (NYSE: PG) and Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced the creation of a new partnership and joint venture (JV) in consumer health care. The JV, to be named PGT Healthcare, will be headquartered in Geneva, Switzerland and will operate in essentially all markets outside of North America. The partnership between P&a Read More »

Friday, October 14, 2011
Teva Completes Acquisition of Cephalon

-- Combined organization will provide customers with a broad spectrum of specialty branded products in addition to the world's largest generic drug portfolio-- JERUSALEM, Oct 14, 2011 (BUSINESS WIRE) -- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has completed its acquisition of Cephalon, Inc. (NASDAQ: CEPH). The combined company will have a significant presence in over 60 countries and generated approximately $20 billion in revenues on a pro-forma basis for the twelve months ended June 2011. "This important transaction reinforces Teva's long term strateg Read More »

Thursday, October 13, 2011
Teva and Cephalon Receive European Commission Approval For Acquisition

JERUSALEM, Israel & FRAZER, Pa., Oct 13, 2011 (BUSINESS WIRE) -- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Cephalon Inc. (NASDAQ: CEPH) announced today that they received approval from the European Commission to proceed with Teva's acquisition of Cephalon. In connection with this approval, Teva is required to divest Cephalon's marketing authorization of generic modafinil in France and grant to the purchaser of this marketing authorization certain additional rights with respect to the entire European Economic Area, including a covenant not to sue effective as of October 2012. Read More »

Friday, October 07, 2011
U.S. Federal Trade Commission Clears Teva's Acquisition of Cephalon

JERUSALEM & FRAZER, Pa., Oct 07, 2011 (BUSINESS WIRE) --Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Cephalon, Inc. (NASDAQ: CEPH) announced today that the U.S. Federal Trade Commission ("FTC") has accepted the proposed consent order in connection with the pending acquisition of Cephalon by Teva and granted early termination of the Hart Scott Rodino waiting period. Under the consent order that has been executed by the parties and accepted for public comment by the FTC, Teva is required to divest two Abbreviated New Drug Applications (ANDAs) for fentanyl citrate lozeng Read More »

Monday, September 26, 2011
Teva Solidifies Japanese Operations with Complete Buyout of Partner's Interest in Teva's Japanese Joint Venture

-- Broader Platform Reinforces Teva's Position in the Fast GrowingJapanese Generics Market -- JERUSALEM, Sep 26, 2011 (BUSINESS WIRE) -- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it will acquire the 50% interest formerly held by Kowa Company Ltd. in Teva's Japanese joint venture for a total purchase price of $150 million. With this acquisition, Teva will own 100% of the former joint venture, which will immediately begin to do business as an important and wholly-owned member of the Teva Group. Teva and Kowa announced the establishment of Teva-Kowa Pharma Co., Read More »

Thursday, September 15, 2011
Teva Announces Drug Development Investment in Cocrystal Discovery Inc. for Novel Antiviral Therapeutics

Teva signs collaboration, option to license and share purchase agreements with CDI CDI will initially develop for Teva an antiviral drug targeting the polymerase enzyme of the Hepatitis C virus Teva retains the option to invest further for development of two additional antiviral or antibacterial compounds JERUSALEM, Sep 15, 2011 (BUSINESS WIRE) -- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has signed a collaboration option to license and share purchase agreements to invest in Cocrystal Discovery Inc. (CDI), a biopharmaceutical company focused on the disco Read More »